Cardiorenal and other diabetes related outcomes with SGLT-2 inhibitors compared to GLP-1 receptor agonists in type 2 diabetes: nationwide observational study

BACKGROUND: Major prospective randomized clinical safety trials have demonstrated beneficial effects of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT-2i) in people with type 2 diabetes and elevated cardiovascular risk, and rec...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Lugner, Moa, Sattar, Naveed, Miftaraj, Mervete, Ekelund, Jan, Franzén, Stefan, Svensson, Ann-Marie, Eliasson, Björn
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7983265/
https://ncbi.nlm.nih.gov/pubmed/33752680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-021-01258-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados